CoChat

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Abstract

Despite recent advances in the use of immunotherapy, only a minority of patients with small cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that targeting the DNA damage response (DDR) proteins PARP and checkpoint kinase 1 (CHK1) significantly increased protein and surface expression of PD-L1. PARP or CHK1 inhibition remarkably potentiated the antitumor effect of PD-L1 blockade and augmented cytotoxic T-cell infiltration in multiple immunocompetent SCLC in vivo models. CD8+ T-cell depletion reversed the antitumor effect, demonstrating the role of CD8+ T cells in combined DDR–PD-L1 blockade in SCLC. We further demonstrate that DDR inhibition activated the STING/TBK1/IRF3 innate immune pathway, leading to increased levels of chemokines such as CXCL10 and CCL5 that induced activation and function of cytotoxic T lymphocytes. Knockdown of cGAS and STING successfully reversed the antitumor effect of combined inhibition of DDR and PD-L1. Our results define previously unrecognized innate immune pathway–mediated immunomodulatory functions of DDR proteins and provide a rationale for combining PARP/CHK1 inhibitors and immunotherapies in SCLC. Significance: Our results define previously unrecognized immunomodulatory functions of DDR inhibitors and suggest that adding PARP or CHK1 inhibitors to ICB may enhance treatment efficacy in patients with SCLC. Furthermore, our study supports a role of innate immune STING pathway in DDR-mediated antitumor immunity in SCLC. See related commentary by Hiatt and MacPherson, p. 584. This article is highlighted in the In This Issue feature, p. 565

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-1020

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 946

Metadata

Authors
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., Fan, Y., Yang, Y., Wang, J., Glisson, B. S., Wistuba, I. I., Sage, J., Heymach, J. V., Gibbons, D. L., & Byers, L. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Stanford Medicine (US)
  • 1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Corresponding author
Byers, Lauren A.
Venue
Cancer Discovery
Published
2019-05-01
Volume
9
Issue
5
Pages
646-661
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2915645504
Cited by
902
References
47
Citations by year
2026: 84 · 2025: 121 · 2024: 116 · 2023: 130 · 2022: 151 · 2021: 154 · 2020: 103 · 2019: 42
FWCI
47.55
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders
  • HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (U01-CA213273, R01-CA207295, P30-CA016672, P50-CA070907)
  • Lung Cancer Research FoundationLung Cancer Research Foundation (LCRF)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Keywords
small cell lung cancer, DNA damage response, PARP inhibitors, CHK1 inhibitor, PD-L1 blockade, immune checkpoint blockade, STING pathway, T cell activation, CD8+ T cells, innate immunity, cGAS, CXCL10, RANTES, antitumor immunity, combination immunotherapy
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, STING Protein, Animals, DNA Damage, Female, Humans, Lung Neoplasms, Lymphocyte Activation, Membrane Proteins, Mice, Nude, Phthalazines, Piperazines, Pyrazines, Pyrazoles, Random Allocation, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Apoptosis, Protein Serine-Threonine Kinases, CD8-Positive T-Lymphocytes, Xenograft Model Antitumor Assays, Protein Kinase Inhibitors, Cell Proliferation, Interferon Regulatory Factor-3, Mice, Small Cell Lung Carcinoma, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.